Back to trial details

Intake questionnaire

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Applying to Rush University Medical Center Rush University Cancer Center Chicago · Chicago, Illinois

Answer a few short questions to share with the research team.

0 of 4 answered

1. Are you 18 years old or older?
2. Have you been diagnosed with Carcinoma, Non-Small-Cell Lung?
3. Are you currently pregnant or breastfeeding?
4. Are you able to travel to Chicago for study visits?